FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565447159> ?p ?o ?g. }

• W2565447159 abstract "Introduction: Gastric cancer is one of the leading types of cancer and the second leading cause of cancer death in the world. Recently, the foci of treatment shift towards not only survival benefit but also better quality of life (QOL) in patients with advanced gastric cancer. Therefore, the development of an auxiliary tool to assess QOL is likely to be required. On the other hand, immune checkpoint blockade by anti-CTLA-4 antibody and anti-PD-1 antibody led to clinical breakthrough for the treatment of patients with advanced cancer. Early phase clinical trial of pembrolizumab in patients with advanced gastric cancer has already been conducted. Pretreatment circulating VEGF have been recently shown to associate with clinical outcome in patients treated with ipilimumab. Certain circulating cytokine levels have been shown to reflect tumor progression and have a prognostic value. Although, it remains obscure whether circulating cytokine levels affect QOL and immune function. In this study, we examined the correlation of circulating cytokine with QOL as well as parameters of immune function such as whole blood cytokine production and the number of peripheral Tregs in patients with advanced gastric cancer. Methods: Subjects comprised 31 patients with unresectable or recurrent gastric cancer. We evaluated plasma cytokine levels and whole blood cytokine production after phytohemagglutinin (PHA) stimulation using the bioplex array system. We also assessed the number of peripheral Tregs by flow cytometry. Health-related QOL was assessed using the Quality of Life Questionnaire (EORTC QLQ-C30). Results: Significant negative correlation was found between plasma VEGF levels and global health status scores (p = 0.0103) as well as physical functioning scale scores (p = 0.0006) and cognitive functioning scale scores (p = 0.0191). Some symptom scale scores (e.g. fatigue, appetite loss) were correlated with plasma VEGF levels. There was a negative correlation between plasma VEGF levels and whole blood IFN-γ production (p = 0.0002). Significant negative relationship existed between the number of peripheral Tregs and plasma IL-6 levels (p Conclusion: These data indicate that the evaluation of plasma VEGF level is likely to be useful to assess QOL such as global health status, physical functioning and cognitive functioning and elevated levels of plasma VEGF might associated with the attenuation of immune function in patients with advanced gastric cancer. Consequently, clinical utility of anti-VEGF therapy combined with immunotherapy is required to investigate in larger clinical studies in the future. Citation Format: Naoyuki Sakamoto, Takeshi Ishikawa, Tetsuya Okayama, Tomoyo Yasuda, Toshifumi Doi, Hideyuki Konishi, Satoshi Kokura, Mari Tanigawa, Kazuko Uno, Yuji Naito, Yoshito Ito, Toshikazu Yoshikawa. Elevated levels of plasma VEGF associated with the attenuation of whole blood IFN-γ production and QOL impairment in patients with advanced gastric cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1326. doi:10.1158/1538-7445.AM2015-1326" @default.
• W2565447159 created "2017-01-06" @default.
• W2565447159 creator A5004262943 @default.
• W2565447159 creator A5023013637 @default.
• W2565447159 creator A5025761309 @default.
• W2565447159 creator A5042716966 @default.
• W2565447159 creator A5044080439 @default.
• W2565447159 creator A5045173926 @default.
• W2565447159 creator A5048831789 @default.
• W2565447159 creator A5051845316 @default.
• W2565447159 creator A5052003452 @default.
• W2565447159 creator A5053874033 @default.
• W2565447159 creator A5061869584 @default.
• W2565447159 creator A5067676082 @default.
• W2565447159 date "2015-08-01" @default.
• W2565447159 modified "2023-09-23" @default.
• W2565447159 title "Abstract 1326: Elevated levels of plasma VEGF associated with the attenuation of whole blood IFN-γ production and QOL impairment in patients with advanced gastric cancer" @default.
• W2565447159 doi "https://doi.org/10.1158/1538-7445.am2015-1326" @default.
• W2565447159 hasPublicationYear "2015" @default.
• W2565447159 type Work @default.
• W2565447159 sameAs 2565447159 @default.
• W2565447159 citedByCount "0" @default.
• W2565447159 crossrefType "proceedings-article" @default.
• W2565447159 hasAuthorship W2565447159A5004262943 @default.
• W2565447159 hasAuthorship W2565447159A5023013637 @default.
• W2565447159 hasAuthorship W2565447159A5025761309 @default.
• W2565447159 hasAuthorship W2565447159A5042716966 @default.
• W2565447159 hasAuthorship W2565447159A5044080439 @default.
• W2565447159 hasAuthorship W2565447159A5045173926 @default.
• W2565447159 hasAuthorship W2565447159A5048831789 @default.
• W2565447159 hasAuthorship W2565447159A5051845316 @default.
• W2565447159 hasAuthorship W2565447159A5052003452 @default.
• W2565447159 hasAuthorship W2565447159A5053874033 @default.
• W2565447159 hasAuthorship W2565447159A5061869584 @default.
• W2565447159 hasAuthorship W2565447159A5067676082 @default.
• W2565447159 hasConcept C121608353 @default.
• W2565447159 hasConcept C126322002 @default.
• W2565447159 hasConcept C143998085 @default.
• W2565447159 hasConcept C203014093 @default.
• W2565447159 hasConcept C2777701055 @default.
• W2565447159 hasConcept C2778690821 @default.
• W2565447159 hasConcept C2780057760 @default.
• W2565447159 hasConcept C2781433595 @default.
• W2565447159 hasConcept C71924100 @default.
• W2565447159 hasConcept C8891405 @default.
• W2565447159 hasConceptScore W2565447159C121608353 @default.
• W2565447159 hasConceptScore W2565447159C126322002 @default.
• W2565447159 hasConceptScore W2565447159C143998085 @default.
• W2565447159 hasConceptScore W2565447159C203014093 @default.
• W2565447159 hasConceptScore W2565447159C2777701055 @default.
• W2565447159 hasConceptScore W2565447159C2778690821 @default.
• W2565447159 hasConceptScore W2565447159C2780057760 @default.
• W2565447159 hasConceptScore W2565447159C2781433595 @default.
• W2565447159 hasConceptScore W2565447159C71924100 @default.
• W2565447159 hasConceptScore W2565447159C8891405 @default.
• W2565447159 hasLocation W25654471591 @default.
• W2565447159 hasOpenAccess W2565447159 @default.
• W2565447159 hasPrimaryLocation W25654471591 @default.
• W2565447159 hasRelatedWork W1998980440 @default.
• W2565447159 hasRelatedWork W2062261501 @default.
• W2565447159 hasRelatedWork W2074564761 @default.
• W2565447159 hasRelatedWork W2114170995 @default.
• W2565447159 hasRelatedWork W2129166800 @default.
• W2565447159 hasRelatedWork W2274321569 @default.
• W2565447159 hasRelatedWork W2394441089 @default.
• W2565447159 hasRelatedWork W2420374885 @default.
• W2565447159 hasRelatedWork W2529586590 @default.
• W2565447159 hasRelatedWork W2565089125 @default.
• W2565447159 hasRelatedWork W2896474249 @default.
• W2565447159 hasRelatedWork W2900042498 @default.
• W2565447159 hasRelatedWork W2966458961 @default.
• W2565447159 hasRelatedWork W2994987525 @default.
• W2565447159 hasRelatedWork W3009590828 @default.
• W2565447159 hasRelatedWork W3033543042 @default.
• W2565447159 hasRelatedWork W3042693689 @default.
• W2565447159 hasRelatedWork W3044353935 @default.
• W2565447159 hasRelatedWork W3102322316 @default.
• W2565447159 hasRelatedWork W3133289372 @default.
• W2565447159 isParatext "false" @default.
• W2565447159 isRetracted "false" @default.
• W2565447159 magId "2565447159" @default.
• W2565447159 workType "article" @default.